Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases

 Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases

Lilly Collaborates with Rigel to Develop RIPK1 Inhibitors for Immunological and Neurodegenerative Diseases

Shots:

  • Rigel to receive $125M up front and is also eligible to receive ~$835M as development, regulatory and commercial milestones as well as royalties, which will vary depending upon Rigel’s clinical development investment
  • Lilly to get an exclusive WW license to Rigel’s RIPK1 inhibitors, including its R552 in all indications. The companies will co-develop R552 at specified contribution levels under which Lilly will be responsible for all costs of global commercialization & Rigel gets the right to co-commercialize R552 in the US
  • Rigel will initiate P-II trials of R552 in 2021. Pursuant to the collaboration, Lilly will solely lead all clinical development of RIPK1 inhibitors in CNS diseases

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: ABC News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post